🧬 Key Insights from Genoskin's Latest Research 🧬 We are excited to share some of the major findings from our newly published study in Allergy EAACI: 1️⃣ We developed a versatile framework for longitudinal profiling of the human skin ecosystem in response to vaccines at the injection site, using a matrix-skin biopsy-silicone ring association that allows for subcutaneous or intradermal delivery while preserving native adipose tissue integrity. 2️⃣ At the organ level, the study deciphered precise sequential events following vaccine injection, including recognition and response to foreign agents, adjustments in skin homeostasis, activation of stress responses, and initiation of immune reactions. 3️⃣ At the single-cell level, the mRNA-1237 COVID-19 vaccine consistently targeted dermal DC/macrophages and mast cells, regardless of the administration route, and triggered substantial transcriptomic changes in the entire myeloid compartment and a significant proportion of CD4 and CD8 T cells. These insights bring us closer to developing safer, more effective vaccines by deepening our understanding of skin immune responses to injected drugs. A huge thank you to our team and collaborators at Infinity - Toulouse Institute for Infectious and Inflammatory Diseases for their relentless pursuit of excellence in research! 🔗 https://lnkd.in/e7FmNYqi #VaccineResearch #ScientificInnovation #Genoskin #AllergyJournal
💡 How can we translate experiments conducted in a preclinical setting to a human context that closely reflects patient conditions? I am excited to share our new publication in #Allergy in partnership between GENOSKIN and Infinity - Toulouse Institute for Infectious and Inflammatory Diseases. Here we introduce a NEW scalable platform for drug development that enables real-time monitoring of the human immune response within natural human skin maintained alive ex vivo for days. Combining advanced bioengineering from Genoskin and multiomics analyzes, we can now understand how skin-resident immune cells react to immunogenic drugs (here we used the mRNA-1273 COVID-19 vaccine as an example) at both organ and single-cell levels. This innovative pipeline not only offers a detailed understanding of tissue immunity but also holds significant promise for advancing new strategies in vaccine and drug development. This work has been performed in majority by Manon Scholaert, Mathias Peries and Emilie Braun and co-led by Emeline Pagès and myself, with the help of our precious collaborators at GENOSKIN and Inserm. #immunogenicity #drug 👉 https://lnkd.in/eQAwFCBX